Clinical Trial Update: CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study of CNCT19 CAR-T therapy in patients with relapsed or refractory diffuse large B-cell lymphoma after autolog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CNCT19 (CNCT19 cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Large B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED